Teva Pharmaceuticals and Sanofi have released positive Phase IIb data for their anti-TL1A agent, which targets ulcerative colitis and Crohn's disease. Analysts believe that this treatment has the potential to be the best in its class and could position the companies competitively against major players like Merck and Roche in the inflammatory bowel disease market.

Additionally, PureTech Health's deupirfenidone, a modified version of Roche's Esbriet, has shown superior results in a Phase IIb trial for patients with idiopathic pulmonary fibrosis (IPF). This success allows PureTech to proceed with finalizing its Phase III program and exploring financing options for the next stages of development.